Frank Rimerman Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$952K Buy
5,194
+12
+0.2% +$2.21K 0.06% 250
2025
Q4
$912K Buy
5,182
+1
+0% +$163 0.06% 247
2025
Q3
$726K Sell
5,181
-187
-3% -$25.3K 0.05% 287
2025
Q2
$674K Buy
+5,368
New +$669K 0.05% 289
2025
Q1
Sell
-3,337
Closed -$510K 519
2024
Q4
$510K Buy
+3,337
New +$563K 0.04% 305
2024
Q3
Sell
-1,179
Closed -$273K 531
2024
Q2
$273K Buy
+1,179
New +$256K 0.02% 465
2024
Q1
Sell
-49
Closed -$12.7K 338
2023
Q4
$12.7K Buy
+49
New +$12K ﹤0.01% 163

Other funds holding BIIB

Frank Rimerman Advisors's BIIB Position: Q1 2026 in Review

Frank Rimerman Advisors increased its Biogen (BIIB) stake by 0.23% in Q1 2026, buying an estimated $2.21K and bringing the position to 5,194 shares worth $952K. The position accounts for 0.06% of the portfolio, ranked #250.

Frank Rimerman Advisors first reported a position in BIIB in Q4 2023 and has held it in 7 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Frank Rimerman Advisors held 5,194 shares of Biogen worth $952K as of Q1 2026.
  • Frank Rimerman Advisors bought 12 Biogen shares in Q1 2026, an estimated $2.21K.
  • Biogen made up 0.06% of Frank Rimerman Advisors's portfolio in Q1 2026, its #250 holding.
  • Frank Rimerman Advisors first reported a position in Biogen in Q4 2023 and has held it in 7 quarters since.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.